Figure 7.
DSP-8658 reduces Aβ burden in the APP/PS1 transgenic mice. APP/PS1 transgenic mice were treated with DSP-8658 in the diet for 3 months. After treatment, cortex and hippocampus were excised and protein was extracted. Concentrations of Aβ1–40 and Aβ1–42 in SDS-soluble (A, C) and RIPA-soluble (B, D) fractions from cortex and hippocampus of APP/PS1 mice were determined by sandwich ELISA. DSP-8658 reduced SDS-soluble Aβ1–40 and Aβ1–42 in cortex and SDS-soluble Aβ1–42 in hippocampus compared with control (mean ± SEM of n = 4, *p < 0.05, **p < 0.01, Student's t test). E, Aβ deposition in the cortex was evaluated by thioflavin S staining and calculated as Aβ-positive area fraction (mean ± SEM of n = 4, *p < 0.05, Student's t test). Scale bar, 250 μm.